PWM
HAE icon

Parkworth Wealth Management’s Haemonetics HAE Stock Holding History

Parkworth Wealth Management’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$149 Hold
2
– – ﹤0.01% 1029
2025
Q1 		$127 Hold
2
– – ﹤0.01% 872
2024
Q4 		$156 Buy
+2
New +$161 ﹤0.01% 836

Other funds holding HAE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RRAM
River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Parkworth Wealth Management's HAE Position: Q2 2025 in Review

Parkworth Wealth Management held its Haemonetics (HAE) position steady in Q2 2025 at 2 shares worth $149. The position accounts for ﹤0.01% of the portfolio, ranked #1029.

Parkworth Wealth Management first reported a position in HAE in Q4 2024 and has held it in 3 quarters since. The position peaked at $156 in Q4 2024. 298 funds tracked by Wall St. Rank hold HAE as of Q2 2025.

  • Parkworth Wealth Management held 2 shares of Haemonetics worth $149 as of Q2 2025.
  • Parkworth Wealth Management left its Haemonetics share count unchanged in Q2 2025.
  • Haemonetics made up ﹤0.01% of Parkworth Wealth Management's portfolio in Q2 2025, its #1029 holding.
  • Parkworth Wealth Management first reported a position in Haemonetics in Q4 2024 and has held it in 3 quarters since.
  • Parkworth Wealth Management's Haemonetics position peaked at $156 in Q4 2024.
  • 298 funds tracked by Wall St. Rank held Haemonetics as of Q2 2025.

Based on Parkworth Wealth Management's 13F filing for Q2 2025, filed 13 Aug 2025.